Get started
Koninklijke Philips N.V.Koninklijke Philips N.V.Koninklijke Philips N.V.

Koninklijke Philips N.V.

No trades
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsBondsETFs

Trade ideas

PHG | Healthcare Co Ready to Launch | LONGKoninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
NYSE:PHGLong
by DivergenceSeeker
PHG long position confirmed Monday 7/28/25Hello, Ayrfolio posts stock trade ideas that can potentially soar up! Our strategy is based on weekly charts and momentum so you must be patient! No day trades here unless the stock soars up intraday! Today we’re covering: STOCK SYMBOL: PHG POSITION: Long TP1 Risk-Reward Ratio: 1.99 TP2 Risk-Reward Ratio: 3.43 Stop Loss: must wait AFTER daily candle closes to exit trade (regular candle, NOT Heiken Ashi) Ultimate Stop Loss: can exit IMMEDIATELY if price reaches this level during any trading hours EXPLANATION: Weekly momentum increased and confirmed on Monday 7/28/25 at $26.46/share. Although the stop losses are listed on the chart, if momentum has been lost then we can exit before price reaches the stop losses. DISCLAIMER: Please do your own due diligence before making any decisions. P.S. - Stocks can soar. YOU can soar. Soaring is possible! -Ayrfolio
NYSE:PHG
by ayrfolio
2
$PHG Shares Surge 46% as it Settles U.S. Respiratory Device CasePhilips ( NYSE:PHG ), the Dutch medical devices giant, experiences a surge in its stock price following a groundbreaking $1.1 billion settlement in the U.S. for personal injury cases linked to the recall of its sleep apnea devices. While the settlement marks a significant milestone for Philips, questions linger about the impact on patient safety and the company's financial future. Philips ( NYSE:PHG ) shares soared by a staggering 46% to reach a two-year high after the company announced a monumental $1.1 billion settlement in the U.S. for personal injury cases tied to the recall of its sleep apnea devices. The agreement, which comes amid concerns over potential cancer risks associated with the devices, has catapulted Philips ( NYSE:PHG ) back into the spotlight, alleviating uncertainty surrounding its legal battles. The company's decision to settle reflects a strategic move to address mounting litigation and restore investor confidence. While Philips ( NYSE:PHG ) vehemently denies any fault or liability, CEO Roy Jakobs emphasized the company's commitment to patient safety and quality, stating, "We have taken important steps in further resolving the consequences of the Respironics recall." Despite the substantial provision for the settlement, analysts are cautiously optimistic about Philips' financial outlook. The settlement amount, significantly lower than anticipated, has assuaged fears of a worst-case scenario, signaling a positive development for the company's bottom line. Barclays analyst Hassan Al-Wakeel remarked that the settlement is a "capped amount" that brings much-needed closure to ongoing litigation. However, challenges remain for Philips ( NYSE:PHG ) as it navigates remaining legal cases in Europe and seeks to regain market trust. While the settlement marks a pivotal moment in the company's journey, questions persist about the long-term impact on its reputation and future growth prospects. With the majority of legal cases now settled, Philips ( NYSE:PHG ) is poised to refocus its efforts on core business operations and strategic initiatives. CEO Roy Jakobs expressed confidence in the company's ability to bounce back, reaffirming full-year guidance and raising cash flow projections. Technical Outlook NYSE:PHG stock is up 46% on Monday's Pre-market trading with a Relative Strength Index (RSI) of 87 which is a clear indication of an overbought scenario traders need to be cautious of a trend reversal. The daily chart pattern shows a symmetrical Triangle pattern in the near term breaking above the ceiling of the previous pivot point.
NYSE:PHGLong
by DEXWireNews
PHG | Strong Positive Volume | LONGKoninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
NYSE:PHGLong
by DivergenceSeeker
Philips shares can Show It's Power Soon.Hello Dear Traders, i Think we have 2 possibility In the near future: something will happen Like Financial recession of 2008 and the all worlds' stocks and shares will fall or they should Rise and go Up A.S.A.P because it's not normal to stay for a long time in Lower Line of Up Trend Cuz it can Break it so Strongly and there will be a Mega Bearish Trend. Result: J.K(Just Kidding) :-D Buy Philips Stock and You will see Profit and benefit of your patience.
EURONEXT:PHIALong
by LadyAzam
A backward stepBig investors seem interested in Philips, and that’s been happening for a while now. For various legal vicissitudes the Stock has had to suffer a pressure from part of some types of investor and for last the collapse happened some days before. However, the trend towards short-term reductions by institutional investors and professional investors has not been affected. The recent collapse seems mostly due to a mass sale by private investors and traders. That’s why I think Philips will go back exactly where he started and then continue his ascent.
EURONEXT:PHIALong
by MarketMiracleAdvisor
1
PHIA | Time to buyPhilips has reached it's (nearly) lowest levels for the last 3-5 years, The reason seems to be a recall of equipment of a value of about 4bl$. In general the company is quite healthy, no debts, positive cashflow, not very impressive, but still good PE and EPS ratios. They have concrete development plans and solid background for upcoming profits. The stock price may in the near future go below 30 euros, down to 27 euros as worst in my opinion. Considering the fundamental background information and technical analysis expectations (which logically support each other), in a year or two, the stock price could reach the 55-60 euros, meaning doubling. Considering the purchase price, background info and technically expected future price, now it seems to be a good time to enter the market. The only drawback investing in PHIA, could be longer return periods, than initially expected. Since the company is not generating high profits, and pays dividends, they might need much longer time to recover and grow further. For the rest, it's a healthy company, strong brand and pretty cheap offer, for those who might like the company as investment item.
EURONEXT:PHIA
by inducto